Immune responses in glioblastoma: An avenue to effective cancer therapy or a mere epiphenomenon?

Current Topics in Microbiology and Immunology

Volumn 265, Issue , 2002, Pages 259-267

  Schluesener, H J ^a   Meyermann, R ^a   Deininger, M ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CHEMOKINE; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; CYTOKINE RECEPTOR; FIBRONECTIN; INTEGRIN; INTERLEUKIN 12; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CYTOKINE PRODUCTION; GENE TRANSFER; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SECOND MESSENGER; TUMOR LOCALIZATION;

EID: 0036130544     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-662-09525-6_13     Document Type: Review

References (83)

1. 3, promotes endothelial cell adhesion and induces angiogenesis in vivo
2. Tumor gene therapy made easy: Allogeneic major histocompatibility complex in the C6 rat glioma model
3. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
4. Immunosuppression and transforming growth factor-β in glioblastoma
5. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
6. T cell-tumor cell: A fatal interaction?
7. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas
8. Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis
9. Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats
10. Immune defects observed in patients with primary malignant brain tumors
11. Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis
12. Angiogenesis in cancer, vascular, rheumatoid and other diseases
13. Addressing tumor blood vessels
14. Anti-angiogenic gene therapy
15. Cytokine gene therapy of gliomas: Induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity
16. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposure to angiostatin
17. Development of systemic immunity to glioblastoma multiforme using tumor cells genetically engineered to express the membrane-associated isoform of macrophage colony-stimulating factor
18. Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest
19. Growth factors in gliomas revisited
20. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
21. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1
22. Molecular genetics of brain tumors
23. Glioblastoma multiforme: The terminator
24. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
25. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas
26. Transforming growth factor beta as a potential tumor progression factor among hyperdipoid glioblastoma cultures: Evidence for the role of platelet-derived growth factor
27. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: A review
28. Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide 11
29. A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response
30. A novel approach to glioma gene therapy: Down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes
31. In situ detection of transforming growth factor-β mRNA in experimental rat glioma and reactive glial cells
32. Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration and adhesion
33. Angiostatin suppresses malignant glioma growth in vivo
34. Vascular endothelial growth factor production is stimulated by ganglioside and TGF-beta isoforms in human glioma cells in vitro
35. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2
36. The CCN family of angiogenic regulators: The integrin connection
37. Microvessel density is a prognostic indicator for patients with astroglial brain tumors
38. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene
39. Coexpression of interleukin-1 beta and interleukin-6 in human brain tumors
40. Tumor angiogenesis a new therapeutic target in gliomas
41. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family
42. A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor
43. The expanding universe of T cell subsets: Th1, Th2 and more
44. Response of microglial cells to experimental rat glioma
45. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas
46. Expression of vascular endothelial growth factor in human brain tumors
47. Selective expression of interleukin-10 gene within glioblastoma multiforme
48. Transforming growth factor-beta 1, -beta 2, and beta 3 secreted by a human glioblastoma cell line. Identification of small and different large latent complexes
49. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms
50. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
51. Endostatin: An endogenous inhibitor of angiogenesis and tumor cell growth
52. From the cover: Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors
53. Human glioma immunobiology in vitro: Implications for immunogene therapy
54. Angiogenesis in malignant gliomas
55. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
56. Up-regulation of vascular endothelial growth factor and its cognate receptors in rat glioma model of tumor angiogenesis
57. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
58. Angiogenesis in malignant primary and metastatic brain tumors
59. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma
60. Distribution and characterization of microglia/macrophages in human brain tumors
61. Modulation of T cell functions by gliomas
62. Inhibition of growth of C6 glioma cells in vivo by expression of antisense endothelial growth factor sequence
63. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors
64. In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes
65. Spontaneous multidrug transport in human glioma is regulated by transforming growth factors type β
66. Tyrosyl-tRNA synthetase: A housekeeping protein and an attractive harbinger of cellular death?
67. Endothelial-monocyte activating polypeptide (EMAP) II, a novel antiangiogenic protein, suppresses tumor growth and induces apoptosis in endothelial cells
68. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
69. Regulation of tumor angiogenesis by organ-specific cytokines
70. Anti-angiogenic gene therapy of malignant glioma
71. Cell-type specific expression of angiopoietin-1 and angiopoietin2 suggests a role in glioblastoma angiogenesis
72. Analysis of cytokine receptor messenger RNA expression in human glioblastoma cells and normal astrocytes by reverse-transcription polymerase chain reaction
73. Expression of the angiogenic factor thymidine phosphorylase in human astrocytic tumors
74. Endothelial-monocyte-activating polypeptide II
75. Cytokines and tumors of the central nervous system
76. Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-gamma, interleukin-7, or B7-1-transfected tumor cells
77. Inhibitors of angiogenesis in a clinical perspective
78. Microglia/macrophage expression of interleukin 10 in human glioblastomas
79. The failure of current immunotherapy for malignant glioma: Tumor derived TGF-β, T-cell apoptosis, and the immune privilege of the brain
80. Angiogenesis in brain tumors; pathobiological and clinical aspects
81. Gene transfer technologies for malignant gliomas
82. Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma